Imago Bio Sciences, Inc. IMGO
We take great care to ensure that the data presented and summarized in this overview for Imago BioSciences, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in IMGO
Top Purchases
Top Sells
About IMGO
Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Insider Transactions at IMGO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 11
2023
|
Amy E. Tapper Chief, Technical Operations |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
141,094
-100.0%
|
$5,079,384
$36.0 P/Share
|
|
Jan 11
2023
|
Robert Baltera Jr. Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
850
-100.0%
|
$30,600
$36.0 P/Share
|
|
Jan 11
2023
|
Jennifer Peppe Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
150,188
-100.0%
|
$5,406,768
$36.0 P/Share
|
|
Jan 11
2023
|
Hsiangyi Chiang Senior Vice President, Finance |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
26,538
-100.0%
|
$955,368
$36.0 P/Share
|
|
Jan 11
2023
|
Michael Arenberg Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
51,532
-100.0%
|
$1,855,152
$36.0 P/Share
|
|
Jan 11
2023
|
Dennis Henner Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
26,095
-100.0%
|
$939,420
$36.0 P/Share
|
|
Jan 11
2023
|
Laura G. Eichorn Chief Financial Officer |
BUY
Disposition due to a tender of shares in a change of control transaction
|
Direct |
246,453
+100.0%
|
$8,872,308
$36.0 P/Share
|
|
Jan 11
2023
|
Hugh Rienhoff Jr Chief Executive Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
501,702
-100.0%
|
$18,061,272
$36.0 P/Share
|
|
Jan 04
2023
|
Hsiangyi Chiang Senior Vice President, Finance |
BUY
Exercise of conversion of derivative security
|
Direct |
19,941
+42.9%
|
$79,764
$4.2 P/Share
|
|
Jan 03
2023
|
Jennifer Peppe Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,379
+0.91%
|
$30,338
$22.76 P/Share
|
|
Jan 03
2023
|
Michael Arenberg Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,145
+4.0%
|
$32,175
$15.45 P/Share
|
|
Jan 03
2023
|
Hugh Rienhoff Jr Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,176
+1.21%
|
$24,352
$2.52 P/Share
|
|
Jan 03
2023
|
Amy E. Tapper Chief, Technical Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
21,261
+4.89%
|
$191,349
$9.83 P/Share
|
|
Jan 03
2023
|
Laura G. Eichorn Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
37,119
+4.84%
|
$334,071
$9.83 P/Share
|
|
Dec 27
2022
|
Michael Arenberg Officer |
SELL
Open market or private sale
|
Direct |
70,508
-58.81%
|
$2,467,780
$35.93 P/Share
|
|
Dec 27
2022
|
Michael Arenberg Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
95,000
+35.23%
|
$1,520,000
$16.95 P/Share
|
|
Dec 27
2022
|
Laura G. Eichorn Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,100
-1.47%
|
$108,500
$35.93 P/Share
|
|
Dec 27
2022
|
Laura G. Eichorn Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,100
+1.45%
|
$6,200
$2.52 P/Share
|
|
Dec 16
2022
|
Michael Arenberg Officer |
SELL
Open market or private sale
|
Direct |
47,750
-65.73%
|
$1,671,250
$35.78 P/Share
|
|
Dec 16
2022
|
Michael Arenberg Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
72,645
+50.0%
|
$1,089,675
$15.45 P/Share
|